GlassScriptPhysician profile
Elliot Keith Mathias
NPI 1871669978
$6,854.34
in general payments reported to CMS, 2019-2025
33 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $545 · 2021: $807 · 2022: $774 · 2023: $1,153 · 2024: $1,725 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $986.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $949.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $477.71 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $438.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $374.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.62 | 2019-2025 | Jardiance |
| Amgen INC. | $235.85 | 2019-2025 | Evenity, Prolia, Repatha |
| Sumitomo Pharma America, INC. | $229.05 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $210.99 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $193.33 | 2019-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $184.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.81 | 2022-2025 | Xifaxan |
| Amarin Pharma, INC. | $102.49 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.95 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.88 | 2021-2023 | Trintellix |
| Madrigal Pharmaceuticals | $72.62 | 2025 | Rezdiffra |
| Allergan, INC. | $65.24 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.56 | 2022-2025 | |
| Eisai INC. | $52.76 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $43.69 | 2022 | |
| Almatica Pharma LLC | $33.34 | 2023-2024 | Loreev Xr, Gralise |
| Medtronic Vascular, INC. | $30.09 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $27.20 | 2020 | |
| Si-Bone, INC. | $25.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $22.12 | 2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $20.62 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.11 | 2025 | Azmiro |
| Janssen Pharmaceuticals, INC | $18.89 | 2019 | |
| Intra-Sana Laboratories | $15.84 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Otsuka America Pharmaceutical, INC. | $13.69 | 2023 | Rexulti |
| Genentech USA, INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.